UK markets open in 6 hours 40 minutes
  • NIKKEI 225

    23,568.40
    +94.13 (+0.40%)
     
  • HANG SENG

    24,786.13
    +31.71 (+0.13%)
     
  • CRUDE OIL

    40.55
    -0.09 (-0.22%)
     
  • GOLD FUTURES

    1,905.80
    +1.20 (+0.06%)
     
  • DOW

    28,363.66
    +152.84 (+0.54%)
     
  • BTC-GBP

    9,869.61
    +1,414.94 (+16.74%)
     
  • CMC Crypto 200

    259.97
    +3.87 (+1.51%)
     
  • ^IXIC

    11,506.01
    +21.31 (+0.19%)
     
  • ^FTAS

    3,268.54
    +7.53 (+0.23%)
     

Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

Orion Oyj
·2-min read

ORION CORPORATION PRESS RELEASE 6 OCTOBER 2020 at 15.00 EEST

Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

Orion will publish Interim Report for January-September 2020 on Wednesday, 21 October 2020 approximately at 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media will be held on Wednesday, 21 October 2020 at 13.30 EEST. The event will be held only online and by conference call.

A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

To participate the conference call, please dial:

Finland: +358 9 817 103 10
Sweden: +46 8 566 426 51
UK: +44 333 300 0804
USA: +1 631 913 1422

PIN: 15529281#

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.